Lenvat 4mg Capsule is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Anaplastic Thyroid Carcinoma (Advanced thyroid cancer) usually occurs in patients above 60 years of age. It is characterized by an enlarged and hard thyroid gland and hoarseness in the voice due to paralysis of the nerve in the voice box. Hepatocellular carcinoma (liver cancer) develops due to preexisting liver conditions such as cirrhosis or chronic hepatitis B infection. Patients who have had an allergic reaction to Lenvat 4mg Capsule or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking Lenvat 4mg Capsule, as it can impair wound healing and increase the risk of bleeding.